A levofloxacin-based triple therapy drug regimen counters Helicobacter pylori far more effectively than do dual therapy levofloxacin regimens.
At one-week, the triple therapy achieved a 90 percent eradication rate with no major adverse effects. The eradication rate did not increase with a longer regimen, report researchers at the University of Pittsburgh Medical Center, Pennsylvania, the Mayo Clinic Rochester, Minnesota and the Catholic University, Rome, Italy.
In an open-label study, the researchers compared the efficacy and tolerability of rabeprazole/levofloxacin dual therapies given for five, seven or 10 days and the same combination with amoxycillin added for seven days. One hundred and sixty patients with infection documented by the C-urea breath test and histology were randomised into four equal groups of 40 patients.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!